Seegene and Samsung Medical Center to Develop MDx Tests for Cancer
April 07, 2011
Seegene and Samsung Medical Center to Develop MDx Tests for Cancer
Seegene will contribute its DPO and READ PCR technologies; while SMC will provide clinical and disease pathology expertise and the first test sites for the new assays.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Seegene Licenses Multiplex Assay Technologies to BioMerieux for Food Safety Testing
April 15, 2013 / GenomeWeb Daily News - Seegene Develops Highly Multiplexed Quantitative Real-Time PCR Chemistry, HPV Genotyping Assay
May 31, 2012 / PCR Insider - Seegene Adds Multiplex HRM Tech to Stable of MDx Assay Chemistries
July 21, 2011 / PCR Insider - Caliper Thinks MDx with Seegene Partnership, LabChip Marketing Strategy
January 13, 2011 / PCR Insider - Seegene to Use Biosearch Fluorophores, Oligos in Molecular Dx Platforms
October 21, 2010 / PCR Insider